The monoclonal antibody developer, which counts EMBL Ventures and GV among its investors, had initially raised $40m when it floated last week.
Arsanis, a US-based immunotherapy drug developer backed by research institute European Molecular Biology Laboratory (EMBL) and internet and technology group Alphabet, closed its initial public offering at $46m on Monday.
Founded in 2010, Arsanis is working on monoclonal antibody immunotherapies that will treat serious infectious diseases. Its lead product candidate ASN100, is being developed to treat a potentially fatal infection-based disease known as Staphylococcus aureus pneumonia.
The company had initially raised $40m last week, issuing 4 million shares priced…
